BioSante Pharmaceuticals, Inc. Announces Bio-E-Gel(TM) NDA Submission
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb. 16, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Bio-E-Gel(TM) (transdermal estradiol gel) to treat moderate-to-severe hot flashes in menopausal women.